N-phenyl-4-(piperazin-1-yl)benzamide | 935856-09-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-phenyl-4-(piperazin-1-yl)benzamide
• 英文别名: N-phenyl-4-piperazin-1-yl-benzamide；N-phenyl-4-piperazin-1-ylbenzamide
• CAS: 935856-09-0
• 化学式: C₁₇H₁₉N₃O
• 分子量: 281.357
• InChiKey: DVHSCUOTDHTHNY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  44.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-phenyl-4-(piperazin-1-yl)benzamide 、 2-(2-溴苯基)乙酸甲酯 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 以44%的产率得到Phenyl-[4-(4-phenylcarbamoyl-phenyl)-piperazin-1-yl]-acetic acid methyl ester
  参考文献：
  名称：

  SUBSTITUTED PIPERAZINES AND PIPERIDINES AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR

  摘要：

  这项发明提供了新型的非肽类NPY Y2受体抑制剂，可用于治疗或预防：抗焦虑障碍或抑郁症；受损的哺乳动物神经组织；通过给予神经营养因子进行治疗的疾病；神经系统疾病；骨质流失；与物质相关的障碍；睡眠/清醒障碍；心血管疾病；肥胖症；或与肥胖相关的疾病。该发明的化合物还可用于调节内分泌功能，特别是垂体和下丘脑腺控制的内分泌功能，并因此可用于治疗或预防排卵障碍和不孕症。

  公开号：

  US20070100141A1
• 作为产物：
  描述：

  4-(4-phenylcarbamoyl-phenyl)-piperazine-1-carboxylic acid tert-butyl ester 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 1.5h， 以76%的产率得到N-phenyl-4-(piperazin-1-yl)benzamide
  参考文献：
  名称：

  SUBSTITUTED PIPERAZINES AND PIPERIDINES AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR

  摘要：

  这项发明提供了新型的非肽类NPY Y2受体抑制剂，可用于治疗或预防：抗焦虑障碍或抑郁症；受损的哺乳动物神经组织；通过给予神经营养因子进行治疗的疾病；神经系统疾病；骨质流失；与物质相关的障碍；睡眠/清醒障碍；心血管疾病；肥胖症；或与肥胖相关的疾病。该发明的化合物还可用于调节内分泌功能，特别是垂体和下丘脑腺控制的内分泌功能，并因此可用于治疗或预防排卵障碍和不孕症。

  公开号：

  US20070100141A1

文献信息

• [EN] PHENYLPIPERAZINE PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) MODULATORS AND THEIR USE<br/>[FR] MODULATEURS PHÉNYLPIPÉRAZINE PROPROTÉINE CONVERTASE SUBTILISINE/KEXINE DE TYPE 9 (PCSK9) ET LEUR UTILISATION
  申请人：PORTOLA PHARM INC

  公开号：WO2017034997A1

  公开（公告）日：2017-03-02

  This invention is related to the field of PCSK9 biology and the composition and methods of use of small organic compounds as ligands for modulation of PCSK9 biological activity. In particular, the invention provides compositions of small organic compounds that modulate circulating levels of low density lipoproteins by altering the conformation of the protein PCSK9. Binding these small organic compound ligands to PCSK9 alters the conformation of the protein, modifying the interaction between PCSK9 and an endogenous low density lipoprotein receptor, and can lead to reduced or increased levels of circulating LDL-cholesterol. High LDL-cholesterol levels are associated with increased risk for heart disease. Low LDL-cholesterol levels may be problematic in other conditions, such as liver dysfunction; thus, there is also utility for small organic compound ligands that can raise LDL levels.

  这项发明涉及PCSK9生物学领域，以及小有机化合物作为调节PCSK9生物活性的配方和使用方法。具体而言，该发明提供了调节低密度脂蛋白循环水平的小有机化合物组合物，通过改变蛋白质PCSK9的构象来实现。将这些小有机化合物配体结合到PCSK9上会改变蛋白质的构象，修改PCSK9与内源性低密度脂蛋白受体之间的相互作用，从而导致循环LDL胆固醇水平降低或增加。高LDL胆固醇水平与心脏疾病风险增加相关。低LDL胆固醇水平可能在其他疾病情况下有问题，比如肝功能障碍；因此，开发能够提高LDL水平的小有机化合物配体也具有实用性。
• Substituted piperazines and piperidines as modulators of the neuropeptide Y2 receptor
  申请人：Janssen Pharmaceutica NV

  公开号：US08183239B2

  公开（公告）日：2012-05-22

  The invention provides novel non-peptidic NPY Y2 receptor inhibitors useful in treating or preventing: anxiolytic disorders or depression; injured mammalian nerve tissue; conditions responsive to treatment through administration of a neurotrophic factor; neurological disorders; bone loss; substance related disorders; sleep/wake disorders; cardiovascular disease; obesity; or an obesity-related disorder. Compounds of the invention are also useful in modulating endocrine functions, particularly endocrine functions controlled by the pituitary and hypothalamic glands, and are therefore useful in the treatment or prevention of inovulation and infertility. The compounds of the present invention are of the formula where Ring T is a heterocycloalkyl ring selected from the group consisting of:

  该发明提供了一种新型的非肽类NPY Y2受体抑制剂，可用于治疗或预防：抗焦虑障碍或抑郁症；受损哺乳动物神经组织；通过神经营养因子的给药治疗反应性疾病；神经系统疾病；骨质流失；与物质相关的疾病；睡眠/清醒障碍；心血管疾病；肥胖症；或肥胖相关疾病。本发明的化合物还可用于调节内分泌功能，尤其是垂体和下丘脑腺体控制的内分泌功能，并因此可用于治疗或预防无排卵和不孕症。本发明的化合物的结构式如下：其中Ring T是从以下群组中选择的杂环烷基环：
• Phenylpiperazine proprotein convertase subtilisin/kexin type 9 (PCSK9) modulators and their use
  申请人：SRX Cardio, LLC

  公开号：US10568882B2

  公开（公告）日：2020-02-25

  This invention is related to the field of PCSK9 biology and the composition and methods of use of small organic compounds as ligands for modulation of PCSK9 biological activity. In particular, the invention provides compositions of small organic compounds that modulate circulating levels of low density lipoproteins by altering the conformation of the protein PCSK9. Binding these small organic compound ligands to PCSK9 alters the conformation of the protein, modifying the interaction between PCSK9 and an endogenous low density lipoprotein receptor, and can lead to reduced or increased levels of circulating LDL-cholesterol. High LDL-cholesterol levels are associated with increased risk for heart disease. Low LDL-cholesterol levels may be problematic in other conditions, such as liver dysfunction; thus, there is also utility for small organic compound ligands that can raise LDL levels.

  本发明涉及 PCSK9 生物学领域以及小分子有机化合物作为配体用于调节 PCSK9 生物活性的组合物和使用方法。特别是，本发明提供了通过改变蛋白质 PCSK9 的构象来调节低密度脂蛋白循环水平的小分子有机化合物组合物。将这些小分子有机化合物配体与 PCSK9 结合可改变该蛋白的构象，改变 PCSK9 与内源性低密度脂蛋白受体之间的相互作用，并可导致循环中低密度脂蛋白胆固醇水平的降低或升高。低密度脂蛋白胆固醇水平高与心脏病风险增加有关。低密度脂蛋白胆固醇水平低可能会对肝功能障碍等其他疾病造成困扰；因此，能提高低密度脂蛋白水平的小分子有机化合物配体也很有用。
• PHENYLPIPERAZINE PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) MODULATORS AND THEIR USE
  申请人：Portola Pharmaceuticals, Inc.

  公开号：EP3337788A1

  公开（公告）日：2018-06-27
• COMPOSITION AND METHODS OF USE OF NOVEL PHENYLALANINE SMALL ORGANIC COMPOUNDS TO DIRECTLY MODULATE PCSK9 PROTEIN ACTIVITY
  申请人：Portola Pharmaceuticals, Inc.

  公开号：US20180250291A1

  公开（公告）日：2018-09-06

  This invention is related to the field of PCSK9 biology and the composition and methods of use of small organic compounds as ligands for modulation of PCSK9 biological activity. In particular, the invention provides compositions of small organic compounds that modulate circulating levels of low density lipoproteins by altering the conformation of the protein PCSK9. Binding these small organic compound ligands to PCSK9 alters the conformation of the protein, modifying the interaction between PCSK9 and an endogenous low density lipoprotein receptor, and can lead to reduced or increased levels of circulating LDL-cholesterol. High LDL-cholesterol levels are associated with increased risk for heart disease. Low LDL-cholesterol levels may be problematic in other conditions, such as liver dysfunction; thus, there is also utility for small organic compound ligands that can raise LDL levels.